Ex vivo expanded patient-derived γδ T-cell immunotherapy enhances neuroblastoma tumor regression in a murine model

Ex vivo expanded patient-derived γδ T-cell immunotherapy enhances neuroblastoma tumor regression in a murine model

An effective therapy regimen for relapsed/refractory high-risk neuroblastoma (NB) includes the anti-GD2 monoclonal antibody, dinutuximab, in combination with temozolomide and irinotecan, supporting a role for chemo-immunotherapy in NB. γδ T cells are an attractive anti-tumor immunotherapy because of...

Full description

Bibliographic Details
Main Authors: Jaquelyn T. Zoine, Kristopher A. Knight, Lauren C. Fleischer, Kathryn S. Sutton, Kelly C. Goldsmith, Christopher B. Doering, H. Trent Spencer
Format: Article
Language:English
Published: Taylor & Francis Group 2019-08-01
Series:OncoImmunology
Subjects:
γδ t cells
neuroblastoma
targeted immunotherapy
temozolomide
dinutuximab
Online Access:http://dx.doi.org/10.1080/2162402X.2019.1593804

Similar Items

Similar Items